Astellas Pharma and Endo subsidiary Endo USA issued voluntary recalls for products they manufacture over concerns of empty tablets and unapproved ingredients, respectively. The recall letters for both ...
MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora ® Cream ...
MALVERN, Pa., March 11, 2025 /PRNewswire/ -- Endo, Inc. (NDOI) today announced it has entered into a definitive agreement to divest its International Pharmaceuticals business, primarily operated ...
(Bloomberg) -- Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments. The agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results